Astrazeneca (AZN) Net Income towards Common Stockholders (2009 - 2026)

Astrazeneca's Net Income towards Common Stockholders history runs 18 years deep, the most recent figure standing at $3.1 billion for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 23.33% year-over-year to $3.1 billion; the TTM figure through Mar 2026 stood at $12.0 billion (up 18.61% YoY), while the FY2025 annual figure was $10.2 billion, up 45.34% from the prior year.
• Net Income towards Common Stockholders was $3.1 billion for Q1 2026 at Astrazeneca, up from $2.8 billion in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $4.0 billion in Q1 2025 to a low of -$372.0 million in Q2 2022.
• Historically, Net Income towards Common Stockholders has averaged $2.0 billion across 5 years, with a median of $1.9 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders slumped 131.26% in 2022, then jumped 588.71% in 2023.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $1.7 billion in 2022, then rose by 4.03% to $1.8 billion in 2023, then fell by 15.78% to $1.5 billion in 2024, then jumped by 84.67% to $2.8 billion in 2025, then grew by 11.19% to $3.1 billion in 2026.
• The last three Net Income towards Common Stockholders figures came in at $3.1 billion (Q1 2026), $2.8 billion (Q4 2025), and $2.6 billion (Q3 2025), per Business Quant data.